Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE Ib, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ONARTUZUMAB IN COMBINATION WITH VEMURAFENIB AND/OR COBIMETINIB IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES

NCT01974258 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01974258
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01974258 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE Ib, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ONARTUZUMAB IN COMBINATION WITH VEMURAFENIB AND/OR COBIMETINIB IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Withdrawn
Start date
February 28, 2014
Completion date
July 31, 2014
Enrollment
0 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms